Tugal-Tutkun Ilknur, Ayranci Ozen, Kasapcopur Ozgür, Kir Nur
Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
J AAPOS. 2008 Dec;12(6):611-3. doi: 10.1016/j.jaapos.2008.08.007. Epub 2008 Oct 19.
Tumor necrosis factor-alpha (TNF-alpha) antagonists have been successfully used in refractory cases of pediatric uveitis.(1-7) We report our experience with the monoclonal anti-TNF-alpha antibody infliximab in the treatment of uveitis in 20 children. Twenty children with noninfectious uveitis were treated with infliximab as an initial line of immunomodulatory therapy (4 children) or for uncontrolled intraocular inflammation despite aggressive immunosuppressive therapy (16 children). Intraocular inflammation was controlled in the short term in all children; resistance developed in 4 children after long-term therapy.
肿瘤坏死因子-α（TNF-α）拮抗剂已成功应用于小儿葡萄膜炎的难治性病例。（1 - 7）我们报告了我们使用单克隆抗TNF-α抗体英夫利昔单抗治疗20例儿童葡萄膜炎的经验。20例非感染性葡萄膜炎患儿接受英夫利昔单抗治疗，作为初始免疫调节治疗方案（4例患儿），或用于尽管积极进行免疫抑制治疗但仍存在无法控制的眼内炎症的情况（16例患儿）。所有患儿的眼内炎症在短期内均得到控制；4例患儿在长期治疗后出现耐药。
